3-(4-甲氧基苯基)苯酚 | 33104-27-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-甲氧基苯基)苯酚
• 英文名称: 4'-methoxybiphenyl-3-ol
• 英文别名: 4'-methoxy-[1,1'-biphenyl]-3-ol；3-(4-Methoxyphenyl)phenol
• CAS: 33104-27-7
• 化学式: C₁₃H₁₂O₂
• 分子量: 200.237
• InChiKey: MEJYXDZTSTYXNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-甲氧基苯基)苯酚 在 sodium hydroxide 、 sodium tetrahydroborate 、 PPA 、 对甲苯磺酸 作用下， 以 xylene 为溶剂， 反应 35.0h， 生成 N-heptyl-8-(4-methoxyphenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-amine
  参考文献：
  名称：

  Synthesis and structure-activity relationships of new ACAT inhibitors

  摘要：

  A series of heterocyclic ureas were synthesized and their ability to inhibit arterial and intestinal ACAT was assessed in animals. The structural modifications carried out in this series led to N-2-(2,4-difluorophenyl)-N-1-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N-1-n-heptylurea 21, which proved to be very active on both the inhibition of aortic ACAT and the inhibition of rat cholesterol intestinal absorption, thus exhibiting a strong hypocholesterolemic effect po in the rat (ED(25) = 0.2 mg/kg).

  DOI：

  10.1016/0223-5234(96)88247-x
• 作为产物：
  描述：

  3-(4-methoxyphenyl)cyclohexanone 在 palladium(II) trifluoroacetate 、 氧气 、 copper diacetate 、 三甲基乙酸 作用下， 110.0 ℃ 、101.33 kPa 条件下， 反应 5.0h， 生成 3-(4-甲氧基苯基)苯酚
  参考文献：
  名称：

  一锅法催化环己酮脱氢成酚和氧化性Heck偶联：香豆素的简便合成方法。

  摘要：

  通过Pd（II）催化的脱氢-氧化Heck环化过程已经开发出了导致高度功能化香豆素的一锅法反应。

  DOI：

  10.1039/c3cc41296b

文献信息

• METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS
  申请人：University College Dublin, National University of Ireland, Dublin

  公开号：US20160102051A1

  公开（公告）日：2016-04-14

  The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

  这项发明通常涉及用于治疗增殖性疾病、病毒感染或两者的方法和化合物。在某些实施例中，该发明提供了一种抗癌或抗病毒化合物，包括一种取代硝基苯氧基苯基、磺酰脲和烷基。在某些实施例中，该发明提供了一种治疗增殖性疾病或病毒感染的方法，包括给予一种结合到血栓素A2受体、对TPalpha（TPα）或TPbeta（TPβ）受体亚型具有优先结合的抗癌或抗病毒化合物。
• 8-Azabicyclo[3.2.1]octane derivatives
  申请人：Napier Elizabeth Susan

  公开号：US20070185156A1

  公开（公告）日：2007-08-09

  The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of the 8-azabicyclo[3.2.1]octane derivative in therapy.

  本发明涉及一种式I的8-氮杂双环[3.2.1]辛烷衍生物，其中每个取代基的定义如规范和声明中所述，或其药学上可接受的盐或溶剂。本发明还涉及一种药物组合物，其包括8-氮杂双环[3.2.1]辛烷衍生物与一种或多种药学上可接受的辅助剂混合，并且涉及在治疗中使用8-氮杂双环[3.2.1]辛烷衍生物。
• Modulation of Spectrokinetic Properties of<i>o</i>-Quinonoid Reactive Intermediates by Electronic Factors: Time-Resolved Laser Flash and Steady-State Photolysis Investigations of Photochromic 6- and 7-Arylchromenes
  作者：Jarugu Narasimha Moorthy、Apurba L. Koner、Subhas Samanta、Ankur Roy、Werner M. Nau

  DOI：10.1002/chem.200801925

  日期：2009.4.20

  cleavage to yield colored o‐quinonoid intermediates. A combined analysis of μs–ms (laser flash) and real‐time kinetic data show that the o‐quinonoid intermediates decay faster when the C2‐aryl and C6‐/C7‐aryl rings contain electron‐donating and electron‐accepting groups, respectively. Similarly, the decay occurs slowly for the reversed scenario, while intermediate decay rates are observed when both substituents

  多种的不同取代的6-和7- arylchromenes如所描绘离岗光敏反应Ç  O键裂解以产生有色ö -quinonoid中间体。对μs–ms（激光闪光）和实时动力学数据的综合分析表明，当C2-芳基和C6- / C7-芳基环分别包含给电子基团和电子接受基团时，邻醌类中间体的衰减更快。类似地，在相反的情况下，衰变缓慢发生，而当两个取代基都是给电子体时，观察到中等的衰变速率。
• [EN] COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE MALADIES LIÉES À L'OXALATE
  申请人：OXALURX INC

  公开号：WO2019165159A1

  公开（公告）日：2019-08-29

  Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

  本文披露了用于调节甘醇酸氧化酶的化合物和组合物，用于治疗与草酸盐相关的疾病，如高草酸尿症，其中调节甘醇酸氧化酶预计对需要治疗的患者具有疗效。还提供了在人类或动物主体中调节甘醇酸氧化酶活性的方法。
• 3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations
  作者：Jing Tang、Feng Liu、Eva Nagy、Lena Miller、Karen A. Kirby、Daniel J. Wilson、Bulan Wu、Stefan G. Sarafianos、Michael A. Parniak、Zhengqiang Wang

  DOI：10.1021/acs.jmedchem.5b01879

  日期：2016.3.24

  achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without siginificantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1

  人类免疫缺陷病毒（HIV）逆转录酶（RT）相关的核糖核酸酶H（RNase H）仍然是未经验证的抗病毒靶标。特异性靶向HIV RNase H的主要挑战来自对RT聚合酶（pol）和整合酶（IN）链转移（ST）抑制作用的普遍缺乏选择性。我们在此报告了三种新颖的3-羟基嘧啶-2,4-二酮（HPD）亚型的合成和生化评估，这些亚型经过精心设计以实现选择性RNase H抑制。生化研究表明，具有N-1甲基的两个亚型（9和10）在低微摩尔范围内抑制RNase H，而未显着抑制RT聚合酶，而N-1未取代的亚型11在亚微摩尔范围内抑制RNase H，在低微摩尔范围内抑制RT聚合酶。亚型11在HIV-1 INST分析中也表现出明显降低的抑制作用，在细胞生存力分析中没有明显的细胞毒性，这表明它可能适合进一步的结构-活性关系（SAR），以鉴定具有抗病毒活性的RNase H抑制剂。